Citable filing context
RMD's research view summarizes recent SEC filing context, starting with management_change from Aug 17, 2026.
| Filed | Item | Context |
|---|---|---|
| Aug 17, 2026 | management_change | Director Ron Taylor will retire at the 2026 Annual Meeting, and Carol Burt will become Lead Director. |
| Aug 6, 2026 | earnings | ResMed reported Q4 fiscal year 2026 revenue of $1.5 billion, a 9% increase year-over-year. |
| Jul 7, 2026 | divestiture | ResMed entered into a definitive agreement to sell its MatrixCare business to Frazier Healthcare Partners for $490 million. |
| Aug 6, 2026 | Guidance: capital_returned_to_shareholders | 1850.00 to not reported |
| Apr 30, 2026 | Guidance: effective_tax_rate | 21.00 to 23.00 |
| Apr 30, 2026 | Guidance: gross_margin | 62.00 to 63.00 |
| Aug 13, 2026 | business | ResMed is a global leader in digital health and cloud-connected medical devices, primarily focused on the sleep and breathing health markets. The company’s core business centers on treating obstructive sleep apnea (OSA) and chronic respiratory conditions like COPD through its AirSense and AirCurve device platforms, mask systems, and life-support ventilators. A key component of its strategy is an integrated digital ecosystem, leveraging cloud-based platforms like AirView and myAir to monitor patient adherence and improve clinical outcomes. ResMed operates in two segments: Sleep and Breathing Health, and Residential Care Software. The latter provides management solutions for home medical equipment, home health, and hospice providers, though the company is currently divesting its MatrixCare business to sharpen its focus on core sleep and respiratory growth. Recent strategic acquisitions, including Noctrix Health (restless legs syndrome) and VirtuOx (diagnostic testing), further expand its clinical portfolio and end-to-end home-based care capabilities. Financial performance is sensitive to global reimbursement policies, particularly U.S. Medicare and Medicaid, and intense competition from both traditional medical device manufacturers and emerging pharmaceutical weight-loss treatments (GLP-1s). The company faces significant regulatory oversight regarding data privacy, AI deployment, and international trade, while maintaining a global manufacturing network to support its operations in over 140 countries. |
| Aug 13, 2026 | mda | ResMed reported strong fiscal year 2026 results, with net revenue increasing 10% to $5.65 billion, driven by robust demand across its Sleep and Breathing Health portfolio. The company’s primary segment, Sleep and Breathing Health, grew 10% to $4.98 billion, bolstered by a 13% increase in mask and accessory sales and a 9% rise in device revenue, including the AirSense 11 platform. The Residential Care Software segment grew 5% to $676 million, supported by the MEDIFOX DAN and HME verticals. Profitability improved significantly, with gross margin expanding to 61.1% from 59.4% in 2025, reflecting manufacturing and logistics efficiencies despite costs related to an Astral device field safety notification. Net income rose to $1.52 billion, or $10.43 per diluted share. Strategic activity included the acquisition of Noctrix Health to address restless legs syndrome and a definitive agreement to divest the $220 million-revenue MatrixCare business for $490 million, expected to close in fiscal 2027. ResMed maintains a solid liquidity position with $1.5 billion in cash and equivalents and full availability under its $1.5 billion revolving credit facility. The company continues to prioritize R&D, investing $378 million in 2026, while navigating evolving global tax landscapes, including the implementation of Pillar Two minimum tax requirements. |
Source: SEC EDGAR filing text and events; period Aug 17, 2026; filed Aug 17, 2026.
RMD company research is available with Aerarium Pro (CAD $10/mo). The five showcase tickers (TSLA, NVDA, AAPL, AMZN, PLTR) and the macro dashboard stay free. Already a subscriber? Sign in to pick up where you left off.